Idorsia (IDRSF) Projected to Release Quarterly Earnings on Thursday

Idorsia (OTCMKTS:IDRSF) is projected to release its results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.2273) per share and revenue of $63.70 million for the quarter.

Idorsia Stock Performance

IDRSF opened at $5.38 on Wednesday. The firm’s 50 day moving average is $5.98 and its 200-day moving average is $5.67. Idorsia has a 52-week low of $3.50 and a 52-week high of $8.19.

Analysts Set New Price Targets

IDRSF has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Idorsia in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

About Idorsia

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company conducts research in areas including central nervous system disorders, cardiovascular disease, immunology and orphan diseases, with the goal of addressing conditions that may have limited treatment options.

Idorsia was established in 2017 following the acquisition of Actelion by Johnson & Johnson. The company was formed to continue Actelion’s drug-discovery and development activities outside the acquired business.